デフォルト表紙
市場調査レポート
商品コード
1441324

多発性骨髄腫治療の世界市場規模、シェア、成長分析、治療タイプ別、流通チャネル別-産業予測、2023~2030年

Global Multiple Myeloma Therapeutics Market Size, Share, Growth Analysis, By Treatment type, By Distribution Channel - Industry Forecast 2023-2030

出版日: | 発行: SkyQuest | ページ情報: 英文 157 Pages | 納期: 3~5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.10円
多発性骨髄腫治療の世界市場規模、シェア、成長分析、治療タイプ別、流通チャネル別-産業予測、2023~2030年
出版日: 2024年02月17日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3~5営業日
  • 全表示
  • 概要
  • 目次
概要

多発性骨髄腫治療の世界市場規模は2022年に266億9,000万米ドルと評価され、2023年の284億2,000万米ドルから2031年には470億4,000万米ドルに成長し、予測期間(2024~2031年)のCAGRは6.5%で成長する展望です。

多発性骨髄腫治療の世界市場は、近年、いくつかの重要な要因によって著しい成長を遂げています。骨髄機能を破壊し、形質細胞の異常増殖と骨の脆弱化をもたらすこの複雑な血液がんは、人口の高齢化と世界の医療コミュニティにおける分子メカニズムに対する理解の深まりにより、注目度が高まっています。科学研究の進歩は、幹細胞移植、免疫調節薬、プロテアソーム阻害薬、化学療法、モノクローナル抗体、支持療法などの標的治療法の開発に道を開いた。製薬会社は新規治療や個別化医療アプローチに多額の投資を行い、業界の競合を激化させています。製薬会社、バイオテクノロジー企業、研究機関の協力により、モノクローナル抗体やCAR-T細胞療法など、有効性が向上し副作用が軽減された革新的な治療法が生まれ、治療法の選択肢が大きく飛躍する兆しを見せています。

目次

エグゼクティブサマリー

  • 市場概要
  • 繁栄と衰退

調査手法

  • 情報調達
  • セカンダリとプライマリデータソース
  • 市場規模の推定
  • 市場の前提条件と制限

親市場の分析

  • 市場概要
  • 市場規模
  • 市場力学
    • 促進要因
    • 機会
    • 抑制要因
    • 課題

主要市場の考察

  • 技術分析
  • 価格分析
  • サプライチェーン分析
  • バリューチェーン分析
  • 市場のエコシステム
  • IP分析
  • 貿易分析
  • スタートアップ分析
  • 原材料の分析
  • イノベーションマトリクス
  • パイプライン製品の分析
  • マクロ経済指標
  • 主要投資の分析
  • 主要成功要因
  • 競合の程度

市場力学と展望

  • 市場力学
    • 促進要因
    • 機会
    • 抑制要因
    • 課題
  • 規制情勢
  • ポーターの分析
  • 将来の混乱についての特別な考察

多発性骨髄腫治療の世界市場:治療タイプ別

  • 市場概要
  • 化学療法とその他の薬剤
  • 従来の化学療法
  • 免疫調節剤
  • プロテアソーム阻害剤
  • ヒストンデアセチラーゼ(HDAC)阻害剤
  • モノクローナル抗体
  • 放射線
  • 幹細胞移植と支持療法

多発性骨髄腫治療の世界市場:流通チャネル別

  • 市場概要
  • 小売薬局とドラッグストア
  • 病院薬局
  • オンライン薬局

多発性骨髄腫治療の世界市場規模:地域別

  • 市場概要
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • スペイン
    • フランス
    • 英国
    • その他の欧州地域
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他のアジア太平洋
  • ラテンアメリカ
    • ブラジル
    • その他のラテンアメリカ地域
  • 中東・アフリカ
    • GCC諸国
    • 南アフリカ
    • その他中東・アフリカ地域

競合情勢

  • 上位5社の比較
  • 主要企業の市場ポジショニング(2021年)
  • 主要市場企業が採用した戦略
  • 主要成功戦略
  • 市場における最近の活動
  • 主要企業の市場シェア(2021年)

主要企業プロファイル

  • Johnson & Johnson(米国)
  • Celgene Corporation(米国)
  • Amgen Inc.(米国)
  • Janssen Pharmaceuticals, Inc.(米国)
  • Bristol Myers Squibb Company(米国)
  • Onyx Pharmaceuticals, Inc.(米国)
  • Merck & Co., Inc.(米国)
  • Karyopharm Therapeutics Inc.(米国)
  • GlaxoSmithKline plc(英国)
  • Sanofi(フランス)
  • Takeda Pharmaceutical Company Limited(日本)
  • Bluebird Bio, Inc.(米国)
  • Daiichi Sankyo Company, Limited(日本)
  • Genmab A/S(デンマーク)
  • AbbVie Inc.(米国)
  • Seattle Genetics, Inc.(米国)
  • Novartis AG(スイス)
  • MorphoSys AG(ドイツ)
  • Kite Pharma, Inc.(米国)
  • Millennium Pharmaceuticals, Inc.(米国)
  • PharmaMar, S.A.(スペイン)
  • Celldex Therapeutics, Inc.(米国)
  • Kyowa Kirin Co., Ltd.(日本)
  • Poseida Therapeutics, Inc.(米国)
  • Glenmark Pharmaceuticals Ltd.(インド)
目次
Product Code: SQMIG35I2237

Global Multiple Myeloma Therapeutics Market size was valued at USD 26.69 billion in 2022 and is poised to grow from USD 28.42 billion in 2023 to USD 47.04 billion by 2031, growing at a CAGR of 6.5% in the forecast period (2024-2031).

The global market for multiple myeloma therapeutics has experienced remarkable growth in recent years, driven by several key factors. This complex hematological cancer, which disrupts bone marrow function and leads to abnormal plasma cell proliferation and bone fragility, has seen increased attention due to the aging population and a greater understanding of its molecular mechanisms within the global health community. Advances in scientific research have paved the way for the development of targeted therapies, including stem cell transplants, immunomodulatory drugs, proteasome inhibitors, chemotherapy, monoclonal antibodies, and supportive care measures. Pharmaceutical companies are heavily investing in novel treatments and personalized care approaches, intensifying competition in the industry. Collaborations between pharmaceutical firms, biotech companies, and research institutions have yielded innovative therapies with improved efficacy and reduced side effects, such as monoclonal antibodies and CAR-T cell therapies, heralding a significant leap forward in treatment options.

Top-down and bottom-up approaches were used to estimate and validate the size of the Multiple Myeloma Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Multiple Myeloma Therapeutics Market Segmental Analysis

By Treatment type, the market is segmented into Chemotherapy and other drugs, Traditional chemotherapy, Immunomodulating agents, Proteasome inhibitors, Histone Deacetylase (HDAC) inhibitors, Monoclonal Antibodies, Radiation, Stem cell transplant and supportive treatment. Retail Pharmacies & Drug Stores, Hospital Pharmacies and Online Pharmacies are the market segments we end up with when division by distribution channel occurs. If we split the market by region, we will be left with the following sectors: North America, Middle East and Africa, Europe, Asia Pacific, and Latin America.

Drivers of the Multiple Myeloma Therapeutics Market

Advancements in Treatment Options have significantly propelled the multiple myeloma therapeutics market forward, with the introduction of innovative medications such as monoclonal antibodies, proteasome inhibitors, and immunomodulatory drugs (IMiDs). These novel therapies, designed to target cancer cells while minimizing harm to healthy cells, have substantially enhanced treatment efficacy, prolonged patient survival rates, and enhanced post-therapy quality of life. Additionally, the Growing Aging Population has contributed to the market's expansion, as older individuals are more susceptible to multiple myeloma, thus increasing demand for efficient treatment options

Restraints in the Multiple Myeloma Therapeutics Market

High Treatment Costs present a notable restraint, as some therapies remain prohibitively expensive, particularly in regions with limited access to healthcare or lower economic status, potentially limiting the adoption of advanced treatments. Moreover, the Complex Disease Characteristics of multiple myeloma, including its genetic and molecular heterogeneity, pose challenges in developing personalized treatment plans tailored to individual patient needs, which could impede the market's growth.

Market Trends of the Multiple Myeloma Therapeutics Market

Key Market Trends include the ongoing focus on Advancements in Targeted Therapies and Immunotherapies, aiming to minimize the side effects associated with traditional chemotherapy by directly targeting cancer cells. Additionally, there's a growing emphasis on Personalized Medicine and Biomarker-driven Approaches, leveraging genetic profiling and biomarkers to identify patient subgroups most likely to benefit from specific treatments, thus optimizing therapeutic outcomes.

Table of Contents

Executive Summary

  • Market Overview
  • Wheel of Fortune

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Parent Market Analysis

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Regulatory Landscape
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
    • Political Impact
    • Economic Impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Global Multiple Myeloma Therapeutics Market by Treatment type

  • Market Overview
  • Chemotherapy and other drugs
  • Traditional chemotherapy
  • Immunomodulating agents
  • Proteasome inhibitors
  • Histone Deacetylase (HDAC) inhibitors
  • Monoclonal Antibodies
  • Radiation
  • Stem cell transplant and supportive treatment

Global Multiple Myeloma Therapeutics Market by Distribution Channel

  • Market Overview
  • Retail Pharmacies & Drug Stores
  • Hospital Pharmacies
  • and Online Pharmacies

Global Multiple Myeloma Therapeutics Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2021
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
    • By Development
    • By Company
    • By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021

Key Company Profiles

  • Johnson & Johnson (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Celgene Corporation (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Amgen Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Janssen Pharmaceuticals, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol Myers Squibb Company (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Onyx Pharmaceuticals, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Karyopharm Therapeutics Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takeda Pharmaceutical Company Limited (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bluebird Bio, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Daiichi Sankyo Company, Limited (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Genmab A/S (Denmark)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AbbVie Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Seattle Genetics, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • MorphoSys AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Kite Pharma, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Millennium Pharmaceuticals, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • PharmaMar, S.A. (Spain)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Celldex Therapeutics, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Kyowa Kirin Co., Ltd. (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Poseida Therapeutics, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Glenmark Pharmaceuticals Ltd. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments